Change search
ReferencesLink to record
Permanent link

Direct link
Serglycin Is Implicated in the Promotion of Aggressive Phenotype of Breast Cancer Cells
Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.
Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Ludwig Institute for Cancer Research. Uppsala University, Science for Life Laboratory, SciLifeLab.
Department of Laboratory Medicine, Division of Medical Protein Chemistry, Lund University, Malmo¨ , Sweden.
Show others and affiliations
2013 (English)In: PLoS ONE, ISSN 1932-6203, Vol. 8, no 10, e78157- p.Article in journal (Refereed) Published
Abstract [en]

Serglycin is a proteoglycan expressed by some malignant cells. It promotes metastasis and protects some tumor cells from complement system attack. In the present study, we show for the first time the in situ expression of serglycin by breast cancer cells by immunohistochemistry in patients' material. Moreover, we demonstrate high expression and constitutive secretion of serglycin in the aggressive MDA-MB-231 breast cancer cell line. Serglycin exhibited a strong cytoplasmic staining in these cells, observable at the cell periphery in a thread of filaments near the cell membrane, but also in filopodia-like structures. Serglycin was purified from conditioned medium of MDA-MB-231 cells, and represented the major proteoglycan secreted by these cells, having a molecular size of similar to 250 kDa and carrying chondroitin sulfate side chains, mainly composed of 4-sulfated (similar to 87%), 6-sulfated (similar to 10%) and non-sulfated (similar to 3%) disaccharides. Purified serglycin inhibited early steps of both the classical and the lectin pathways of complement by binding to C1q and mannose-binding lectin. Stable expression of serglycin in less aggressive MCF-7 breast cancer cells induced their proliferation, anchorage-independent growth, migration and invasion. Interestingly, over-expression of serglycin lacking the glycosaminoglycan attachment sites failed to promote these cellular functions, suggesting that glycanation of serglycin is a pre-requisite for its oncogenic properties. Our findings suggest that serglycin promotes a more aggressive cancer cell phenotype and may protect breast cancer cells from complement attack supporting their survival and expansion.

Place, publisher, year, edition, pages
2013. Vol. 8, no 10, e78157- p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-211789DOI: 10.1371/journal.pone.0078157ISI: 000326373800014OAI: diva2:668881
Available from: 2013-12-02 Created: 2013-12-02 Last updated: 2013-12-12Bibliographically approved

Open Access in DiVA

fulltext(3226 kB)155 downloads
File information
File name FULLTEXT01.pdfFile size 3226 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Moustakas, Aristidis
By organisation
Ludwig Institute for Cancer ResearchScience for Life Laboratory, SciLifeLab
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 155 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 274 hits
ReferencesLink to record
Permanent link

Direct link